Abbott atrasentan filing delay
Executive Summary
Abbott will not file NDA for oncologic agent atrasentan (ABT-627) until 2004, following the failure of drug to reach its primary endpoint of time-to-progression in a Phase III trial evaluating patients with advanced metastatic hormone-refractory prostate cancer. Abbott previously hoped to file in late 2003 (1"The Pink Sheet" July 2, 2001, p. 22)...
You may also be interested in...
Abbott Will Study Prostate Cancer Drug Atrasentan For Early-Stage/Prevention
Abbott plans to file an NDA for its prostate cancer therapy atrasentan in late 2003, the company told securities analysts at its June 21 R&D Day in New York City.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.